

# INVESTOR NEWSLETTER

FEBRUARY 2023

Dear Abbott Investor,

Just several weeks into the new year and our product pipeline investments already are paying off, with multiple launches and approvals that are moving people beyond their limitations and helping them take control of their health like never before.

Innovations like Navitor, our [latest-generation system](#) for people with severe aortic stenosis, and our [Proclaim XR spinal cord stimulation \(SCS\) system](#) for painful nerve damage that can occur in people with diabetes. These advancements follow the December 2022 approval of our [Eterna \(SCS\) system](#), the world's smallest implantable, rechargeable SCS system for chronic pain.

We're projecting this momentum to continue through 2023. Our highly productive pipeline, coupled with our diversified business model, is helping us set the stage for continued strong performance.

Please check out the stories below for more details. If you missed previous newsletters, you can access our [archive here](#).

Scott Leinenweber  
Vice President, Investor Relations, Licensing and Acquisitions  
Abbott

## ADVANCING OUR PIPELINE



### Meet Navitor: Key Add to Structural Heart Portfolio

U.S. approval of Navitor solidifies Abbott's competitiveness in the TAVI market.



### Poised for Growth Amid Uncertain Environment

Abbott Chairman and CEO on product pipeline, biowearables and COVID testing.



### Partnerships Changing Diabetes Management

Abbott is connecting its tech with major insulin delivery systems.

## CONTINUED RESILIENCY



### Abbott Q4 Earnings

Key numbers and highlights from the company's fourth quarter and full year.

For the latest on what's happening at Abbott, visit us at [www.abbottinvestor.com](http://www.abbottinvestor.com) or follow us on [Twitter](#) and [LinkedIn](#).



[UNSUBSCRIBE](#) | [PRIVACY POLICY](#)

©2023 Abbott. All Rights Reserved.

Abbott | 100 Abbott Park Road | Abbott Park, IL 60044 | (224) 667-6100